Vir Advances HBV, Flu Programs While Focused On COVID-19
Company Brought In Significant Cash Before And After Its IPO
Vir began pursuing immunological approaches to infectious diseases three years before its COVID-19 work. Its hepatitis B, flu and HIV clinical trials are delayed about six months due to coronavirus-related issues.
You may also be interested in...
Vir’s George Scangos, Westlake Village BioPartners’ Sean Harper, Kronos Bio’s Norbert Bischofberger, Scorpion’s Axel Hoos and Eikon’s Roy Baynes discuss the experiences they bring and the challenges they have faced in the transition from large drug makers to small biotechs.
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.